Enanta Pharmaceuticals, Inc.

NASDAQ:ENTA

Biotechnology

Healthcare
$8.23 -0.67%

-$0.09 today

Market cap
$239.70M
Beta
0.99
P/E (TTM)
-4.3
EPS (TTM)
-$2.90
52W Low $6.44High $17.15

Volume 0.81M

Average 0.17M

ENTA EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Enanta Pharmaceuticals, Inc.NASDAQ: ENTA

EBITDA · Q2 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q2 FY2026 EBITDA was -$8.56M, compared with -$21.03M a year earlier. Trailing-twelve-month EBITDA was -$46.56M.

Context

  • EBITDA amounted to 108.4% of revenue in FY2025, down 46.2 pp from a year earlier.
  • EBITDA grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 4 analysts of -$52.71M (+25.5%) for the fiscal year ending Sep 2026, a slowdown from the +32.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$8.56M-12.6% QoQ
Last fiscal yearSep 2025
-$70.78M+32.3% YoY
LTMMar 2026
-$46.56M+46.6% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+59.3%+38.1%-21.2 pp
1 year+32.3%+25.5%-6.8 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(70.78M) USD
Year-over-year change
+32.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How ENTA compares with its peers on the latest reported figures

  • ENTA's LTM Mar 2026 EBITDA of -$46.56M is the 2nd highest of the 11 companies compared; the peer median is -$75.7M.
  • Its year-over-year change of +46.6% is the 2nd highest of 11, against a peer median of +9.7%.
  • EBITDA amounts to 67.3% of revenue for ENTA, versus a peer median of 455.3%.
ENTA Competitors Peer median
EBITDA for ENTA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ASMBAssembly Biosciences, Inc.LTM Mar 2026-$6.26M +84.1%—8.8%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026-$46.56M +46.6%—67.3%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026-$50.77M +11.7%——
IMRXImmuneering CorporationLTM Mar 2026-$58.85M +7.0%——
FHTXFoghorn Therapeutics Inc.LTM Mar 2026-$72.53M +7.7%—257.0%
TNYATenaya Therapeutics, Inc.LTM Mar 2026-$75.47M +22.0%—33540.9%
PYXSPyxis Oncology, Inc.LTM Mar 2026-$75.93M +0.5%—547.9%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026-$76.13M +39.6%—455.3%
CRBUCaribou Biosciences, Inc.LTM Mar 2026-$111.97M +23.4%—999.5%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026-$112.54M -37.5%—308.4%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026-$179.89M -30.1%——
Peer median (excluding ENTA) -$75.7M+9.7%—455.3%

Competitors are the stored peer set for ENTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue97.07M86.16M79.2M67.64M65.32M
Cost of Revenue00004.59M
Gross Profit97.07M86.16M79.2M67.64M60.74M
Gross Margin100.0%100.0%100.0%100.0%93.0%
Research & Development174.11M164.52M163.52M131.48M106.74M
Selling, General & Admin32.54M45.48M52.89M57.85M43.93M
Operating Expenses206.65M210M216.41M189.33M146.09M
Depreciation & Amortization3.33M2.97M2.37M2.34M5.09M
EBITDA(104.25M)(119.22M)(123.48M)(104.51M)(70.78M)
EBITDA Margin-107.4%-138.4%-155.9%-154.5%-108.4%
Operating Income(109.57M)(123.84M)(137.21M)(121.69M)(85.35M)
Operating Margin-112.9%-143.7%-173.2%-179.9%-130.7%
Interest Income2.02M1.57M11.36M14.77M9.48M
Interest Expense005.15M10.94M7.68M
Other Income / Expenses1.99M1.66M6.21M3.9M1.8M
Income Before Tax(107.58M)(122.19M)(131M)(117.79M)(83.55M)
Pre-Tax Margin-110.8%-141.8%-165.4%-174.2%-127.9%
Income Tax Expense(28.58M)(433K)2.82M(1.74M)(1.66M)
Net Income(79M)(121.76M)(133.82M)(116.05M)(81.89M)
Net Margin-81.4%-141.3%-169.0%-171.6%-125.4%
EPS (Basic)(3.92)(5.91)(6.38)(5.48)(3.84)
EPS (Diluted)(3.92)(5.91)(6.38)(5.48)(3.84)
Weighted Avg Shares20.17M20.6M20.97M21.16M21.34M
Weighted Avg Shares (Diluted)20.17M20.6M20.97M21.16M21.34M

Enanta Pharmaceuticals, Inc.

NASDAQ:ENTA

Intrinsic Alpha fair value

Locked

Current Price

$8.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.